Subcutaneous Efgartigimod Expands Payer Potential For Argenx’s Drug
Offers gMG Patients Freedom From I.V. Treatment
With positive Phase III data for the injectable version of its myasthenia gravis therapy, the company expects most patients to use it over intravenous Vyvgart, opening more avenues for reimbursement.
